ASX:PBP Probiotec (PBP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Probiotec Stock (ASX:PBP) 30 days 90 days 365 days Advanced Chart Get Probiotec alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume26,253 shsAverage VolumeN/AMarket CapitalizationA$242.34 millionP/E Ratio21.99Dividend Yield2.43%Price TargetN/AConsensus RatingN/A Company Overview Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia. Read More Receive PBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Probiotec and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBP Stock News HeadlinesMoneyTalks: Brokers name ASX-listed health stocks Percheron and Probiotec as ones to watchApril 8, 2024 | msn.com2 Incredible Dividend Growers to Buy Hand Over Fist in MarchMarch 27, 2024 | ca.finance.yahoo.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 27 at 2:00 AM | InvestorPlace (Ad)Probiotec (ASX:PBP) shareholders have earned a 15% CAGR over the last five yearsMarch 27, 2024 | finance.yahoo.comProbiotec Limited's (ASX:PBP) CEO Compensation Is Looking A Bit Stretched At The MomentNovember 8, 2023 | finance.yahoo.comProbiotec's (ASX:PBP) investors will be pleased with their strong 103% return over the last five yearsOctober 6, 2023 | finance.yahoo.comWhile insiders own 31% of Probiotec Limited (ASX:PBP), retail investors are its largest shareholders with 41% ownershipSeptember 19, 2023 | finance.yahoo.comInvesco S&P 500 BuyWrite ETF (ARCA:PBP), Quotes and News SummaryAugust 29, 2023 | benzinga.comSee More Headlines PBP Stock Analysis - Frequently Asked Questions How were Probiotec's earnings last quarter? Probiotec Limited (ASX:PBP) posted its quarterly earnings data on Tuesday, February, 26th. The company reported $0.02 earnings per share for the quarter. Probiotec had a net margin of 5.15% and a trailing twelve-month return on equity of 13.26%. What other stocks do shareholders of Probiotec own? Based on aggregate information from My MarketBeat watchlists, some other companies that Probiotec investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU), VelocityShares 1x Long VSTOXX Futures ETN (EVIX) and First Trust United Kingdom AlphaDEX Fund (FKU). Company Calendar Last Earnings2/26/2019Today8/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolASX:PBP CIKN/A Webwww.probiotec.com.au Phone61 3 9278 7555FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A$0.10 Trailing P/E Ratio21.99 Forward P/E RatioN/A P/E GrowthN/ANet IncomeA$8.69 million Net Margins5.15% Pretax MarginN/A Return on Equity13.26% Return on Assets5.09% Debt Debt-to-Equity Ratio100.87 Current Ratio0.81 Quick Ratio1.04 Sales & Book Value Annual SalesA$221.22 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow16.79 Book ValueA$1.07 per share Price / BookN/AMiscellaneous Outstanding Shares81,320,000Free FloatN/AMarket CapA$242.34 million OptionableNot Optionable Beta0.44 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (ASX:PBP) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Probiotec Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Probiotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.